Laboratorios Farmaceuticos ROVI (ROVI.MC) Stock Price

Laboratorios Farmaceuticos ROVI Price

BME·CLOSED
58.80EUR+0.25 (+0.43 %)
Market closed

Revenue has compounded at 12.6% per year over the past 19 years to 743.48 M EUR. Earnings per share have grown at 12.2% per year over the last 15 years. Laboratorios Farmaceuticos ROVI's net margin stands at 18.9%, down from 23.6% several years earlier. Laboratorios Farmaceuticos ROVI currently offers a dividend yield of about 1.59%. The payout ratio is around 34% of earnings. The dividend has grown at 15.7% per year over the past 17 years. Analysts set a median price target of 85.07 EUR, implying 44.7% above the current price. Of 16 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 13% above its 52-week low.

Laboratorios Farmaceuticos ROVI stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Laboratorios Farmaceuticos ROVI over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Laboratorios Farmaceuticos ROVI stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Laboratorios Farmaceuticos ROVI's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Laboratorios Farmaceuticos ROVI Stock Price History
DateLaboratorios Farmaceuticos ROVI Price
8/3/202658.80 EUR
7/31/202658.55 EUR
7/30/202659.30 EUR
7/29/202659.55 EUR
7/28/202659.20 EUR
7/27/202659.25 EUR
7/24/202658.80 EUR
7/23/202657.15 EUR
7/22/202656.20 EUR
7/21/202654.70 EUR
7/20/202654.05 EUR
7/17/202653.80 EUR
7/16/202653.70 EUR
7/15/202653.80 EUR
7/14/202653.65 EUR
7/13/202654.20 EUR
7/10/202656.00 EUR
7/9/202656.15 EUR
7/8/202656.35 EUR
7/7/202657.00 EUR
7/6/202657.10 EUR
7/3/202656.85 EUR
7/2/202657.40 EUR
7/1/202657.50 EUR
6/30/202657.85 EUR
6/29/202658.70 EUR
6/26/202658.60 EUR
6/25/202659.25 EUR
6/24/202659.40 EUR
6/23/202659.10 EUR
6/22/202658.70 EUR
6/19/202658.15 EUR
6/18/202658.60 EUR
6/17/202658.05 EUR
6/16/202658.40 EUR
6/15/202659.40 EUR
6/12/202658.85 EUR
6/11/202658.35 EUR
6/10/202658.05 EUR
6/9/202657.60 EUR
6/8/202658.70 EUR
6/5/202659.50 EUR
6/4/202658.00 EUR
6/3/202657.60 EUR
6/2/202657.90 EUR
6/1/202659.00 EUR
5/29/202659.60 EUR
5/28/202659.70 EUR
5/27/202660.90 EUR
5/26/202660.90 EUR
5/25/202659.80 EUR
5/22/202659.55 EUR
5/21/202659.95 EUR
5/20/202658.85 EUR
5/19/202658.20 EUR
5/18/202658.60 EUR
5/15/202658.95 EUR
5/14/202659.40 EUR
5/13/202659.85 EUR
5/12/202661.10 EUR
5/11/202662.10 EUR
5/8/202662.85 EUR
5/7/202663.05 EUR
5/6/202667.10 EUR
5/5/202679.90 EUR
5/4/202679.40 EUR
4/30/202679.40 EUR
4/29/202678.65 EUR
4/28/202679.70 EUR
4/27/202680.70 EUR
4/24/202681.10 EUR
4/23/202684.90 EUR
4/22/202685.35 EUR
4/21/202685.40 EUR
4/20/202685.55 EUR
4/17/202685.10 EUR
4/16/202684.25 EUR
4/15/202684.60 EUR
4/14/202684.85 EUR
4/13/202683.85 EUR
4/10/202683.35 EUR
4/9/202682.45 EUR
4/8/202682.55 EUR
4/7/202680.85 EUR
4/2/202682.65 EUR
4/1/202682.35 EUR
3/31/202680.75 EUR
3/30/202679.80 EUR
3/27/202678.90 EUR
3/26/202679.35 EUR
3/25/202679.30 EUR
3/24/202678.55 EUR
3/23/202678.00 EUR
3/20/202678.40 EUR
3/19/202679.00 EUR
3/18/202680.50 EUR
3/17/202680.00 EUR
3/16/202679.85 EUR
3/13/202679.00 EUR
3/12/202680.00 EUR
3/11/202679.85 EUR
3/10/202683.05 EUR
3/9/202680.30 EUR
3/6/202680.85 EUR
3/5/202680.70 EUR
3/4/202681.25 EUR
3/3/202681.50 EUR
3/2/202683.30 EUR
2/27/202684.75 EUR
2/26/202684.60 EUR
2/25/202682.05 EUR
2/24/202678.20 EUR
2/23/202677.95 EUR
2/20/202678.55 EUR
2/19/202679.05 EUR
2/18/202678.55 EUR
2/17/202677.60 EUR
2/16/202677.30 EUR
2/13/202677.00 EUR
2/12/202677.45 EUR
2/11/202677.15 EUR
2/10/202675.20 EUR
2/9/202674.50 EUR
2/6/202672.85 EUR
2/5/202673.00 EUR
2/4/202673.55 EUR
2/3/202672.85 EUR
2/2/202672.85 EUR
1/30/202671.90 EUR
1/29/202672.50 EUR
1/28/202673.00 EUR
1/27/202674.00 EUR
1/26/202672.65 EUR
1/23/202673.00 EUR
1/22/202673.60 EUR
1/21/202672.15 EUR
1/20/202672.10 EUR
1/19/202671.10 EUR
1/16/202672.20 EUR
1/15/202670.05 EUR
1/14/202669.90 EUR
1/13/202669.05 EUR
1/12/202669.10 EUR
1/9/202668.45 EUR
1/8/202668.15 EUR
1/7/202667.50 EUR
1/6/202666.00 EUR
1/5/202664.90 EUR
1/2/202663.35 EUR
12/31/202563.50 EUR
12/30/202563.40 EUR
12/29/202563.10 EUR
12/24/202562.70 EUR
12/23/202562.50 EUR
12/22/202562.60 EUR
12/19/202562.10 EUR
12/18/202561.90 EUR
12/17/202560.60 EUR
12/16/202560.55 EUR
12/15/202562.90 EUR
12/12/202562.25 EUR
12/11/202561.85 EUR
12/10/202561.45 EUR
12/9/202560.20 EUR
12/8/202560.20 EUR
12/5/202559.85 EUR
12/4/202560.00 EUR
12/3/202559.75 EUR
12/2/202559.20 EUR
12/1/202560.00 EUR
11/28/202559.45 EUR
11/27/202558.80 EUR
11/26/202558.70 EUR
11/25/202558.45 EUR
11/24/202558.65 EUR
11/21/202557.95 EUR
11/20/202557.60 EUR
11/19/202558.50 EUR
11/18/202558.25 EUR
11/17/202558.30 EUR
11/14/202558.75 EUR
11/13/202558.85 EUR
11/12/202559.15 EUR
11/11/202559.15 EUR
11/10/202556.80 EUR
11/7/202554.95 EUR
11/6/202555.00 EUR
11/5/202557.65 EUR
11/4/202558.90 EUR
11/3/202559.50 EUR
10/31/202561.10 EUR
10/30/202562.00 EUR
10/29/202563.25 EUR
10/28/202563.30 EUR
10/27/202563.95 EUR
10/24/202564.40 EUR
10/23/202564.55 EUR
10/22/202564.35 EUR
10/21/202564.05 EUR
10/20/202560.25 EUR
10/17/202559.95 EUR
10/16/202560.25 EUR
10/15/202559.80 EUR
10/14/202558.45 EUR
10/13/202558.70 EUR
10/10/202557.15 EUR
10/9/202558.05 EUR
10/8/202558.80 EUR
10/7/202558.90 EUR
10/6/202560.50 EUR
10/3/202561.15 EUR
10/2/202560.00 EUR
10/1/202559.80 EUR
9/30/202558.15 EUR
9/29/202556.65 EUR
9/26/202556.05 EUR
9/25/202556.60 EUR
9/24/202558.05 EUR
9/23/202558.65 EUR
9/22/202558.80 EUR
9/19/202559.15 EUR
9/18/202558.65 EUR
9/17/202559.40 EUR
9/16/202559.35 EUR
9/15/202559.90 EUR
9/12/202560.55 EUR
9/11/202560.15 EUR
9/10/202559.40 EUR
9/9/202559.65 EUR
9/8/202559.90 EUR
9/5/202559.65 EUR
9/4/202559.75 EUR
9/3/202558.15 EUR
9/2/202558.20 EUR
9/1/202559.00 EUR
8/29/202558.00 EUR
8/28/202558.35 EUR
8/27/202557.50 EUR
8/26/202557.20 EUR
8/25/202558.30 EUR
8/22/202557.75 EUR
8/21/202557.05 EUR
8/20/202557.35 EUR
8/19/202557.45 EUR
8/18/202557.25 EUR
8/15/202556.40 EUR
8/14/202556.10 EUR
8/13/202555.95 EUR
8/12/202554.10 EUR
8/11/202553.70 EUR
8/8/202553.75 EUR
8/7/202553.10 EUR
8/6/202552.00 EUR
8/5/202553.05 EUR
8/4/202553.15 EUR
Access this data via the Eulerpool API
Get Free API Key

Laboratorios Farmaceuticos ROVI Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
829.51 M EUR
220.25 M EUR
170.34 M EUR
Jan 1, 2024
763.75 M EUR
179.55 M EUR
136.88 M EUR
Jan 1, 2025
743.48 M EUR
174.90 M EUR
140.44 M EUR
Jan 1, 2026 (e)
771.18 M EUR
205.76 M EUR
131.54 M EUR
Jan 1, 2027 (e)
890.97 M EUR
237.72 M EUR
176.75 M EUR
Jan 1, 2028 (e)
970.89 M EUR
259.05 M EUR
215.45 M EUR
Jan 1, 2029 (e)
1.05 B EUR
280.33 M EUR
244.82 M EUR
Jan 1, 2030 (e)
1.12 B EUR
299.11 M EUR
291.31 M EUR

Laboratorios Farmaceuticos ROVI Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 4:51 PM
 
REVENUET EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMET EUR
EBITB EUR
EBIT MARGIN%
NET INCOMEB EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
––––––––––––––––
3.367.723.7710.1825.749.9754.6526.081.47-7.96-2.623.7715.438.998.256.76
60.1657.7460.7357.4356.1757.5259.2663.5358.2662.6560.7060.7060.7060.7060.7060.70
––––––––––––––––
0.020.030.020.020.040.070.180.260.220.180.170.210.240.260.280.30
8.5410.576.915.6111.0217.6628.2431.2126.5423.4623.4226.5926.6326.7026.6726.67
0.020.030.020.020.040.060.150.200.170.140.140.130.180.220.240.29
-20.8336.84-34.62–129.4156.41150.8230.07-14.57-20.002.94-6.4334.3522.1613.4919.26
0.170.140.180.120.080.180.380.961.291.100.941.121.351.62––
6.25-17.6528.57-33.33-33.33125.00111.11152.6334.38-14.73-14.5519.1520.5420.00––
49.3249.2849.3255.3855.3855.3953.9153.3751.8251.1251.1551.1551.1551.1551.1551.15
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Laboratorios Farmaceuticos ROVI generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Laboratorios Farmaceuticos ROVI retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Laboratorios Farmaceuticos ROVI's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Laboratorios Farmaceuticos ROVI has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Laboratorios Farmaceuticos ROVI's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Laboratorios Farmaceuticos ROVI stock margins

The Laboratorios Farmaceuticos ROVI margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Laboratorios Farmaceuticos ROVI. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Laboratorios Farmaceuticos ROVI.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
59.32 %
28.27 %
23.60 %
Jan 1, 2022
63.55 %
31.29 %
24.42 %
Jan 1, 2023
58.27 %
26.55 %
20.53 %
Jan 1, 2024
62.63 %
23.51 %
17.92 %
Jan 1, 2025
60.75 %
23.52 %
18.89 %
Jan 1, 2026 (e)
60.75 %
26.68 %
17.06 %
Jan 1, 2027 (e)
60.75 %
26.68 %
19.84 %
Jan 1, 2028 (e)
60.75 %
26.68 %
22.19 %

Laboratorios Farmaceuticos ROVI Stock Revenue, EBIT, Earnings per Share

The Laboratorios Farmaceuticos ROVI earnings per share therefore indicates how much revenue Laboratorios Farmaceuticos ROVI has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
12.03 EUR
3.40 EUR
2.84 EUR
Jan 1, 2022
15.32 EUR
4.79 EUR
3.74 EUR
Jan 1, 2023
16.01 EUR
4.25 EUR
3.29 EUR
Jan 1, 2024
14.94 EUR
3.51 EUR
2.68 EUR
Jan 1, 2025
14.54 EUR
3.42 EUR
2.75 EUR
Jan 1, 2026 (e)
15.06 EUR
4.02 EUR
2.57 EUR
Jan 1, 2027 (e)
17.40 EUR
4.65 EUR
3.45 EUR
Jan 1, 2028 (e)
18.96 EUR
5.06 EUR
4.21 EUR

Laboratorios Farmaceuticos ROVI business model & stock analysis

Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products.

Laboratorios Farmaceuticos ROVI SWOT Analysis

Strengths

Laboratorios Farmaceuticos ROVI SA has several strengths that contribute to its success:

  • Strong market presence and brand reputation.
  • Diverse product portfolio offering a wide range of pharmaceuticals.
  • Advanced research and development capabilities for innovative drugs.
  • Effective distribution network ensuring wide product availability.
  • Robust financial performance and solid profitability.

Weaknesses

Despite its strengths, Laboratorios Farmaceuticos ROVI SA also has some weaknesses:

  • Dependency on a few key products for a significant portion of revenues.
  • Limited geographical presence, concentrated mainly in certain regions.
  • Relatively low market share compared to larger pharmaceutical companies.
  • High research and development costs impacting profitability.

Opportunities

There are several opportunities available for Laboratorios Farmaceuticos ROVI SA:

  • Expanding into new international markets to diversify revenue streams.
  • Leveraging technological advancements to develop innovative products.
  • Collaborating with other pharmaceutical companies for joint research and development.
  • Focusing on emerging markets with growing healthcare needs.

Threats

Laboratorios Farmaceuticos ROVI SA faces certain threats that may impact its business:

  • Intense competition from other pharmaceutical companies.
  • Changes in regulations and government policies affecting the industry.
  • Economic downturns leading to decreased consumer spending on healthcare.
  • Potential patent expirations and generic drug competition.

Laboratorios Farmaceuticos ROVI Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Laboratorios Farmaceuticos ROVI historical P/E ratio, EBIT multiple, and P/S ratio

Laboratorios Farmaceuticos ROVI annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Laboratorios Farmaceuticos ROVI shares outstanding

The number of shares of Laboratorios Farmaceuticos ROVI was 51.15 M in 2025. This indicates how many shares Laboratorios Farmaceuticos ROVI is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
53.91 M Stocks
Jan 1, 2022
53.37 M Stocks
Jan 1, 2023
51.82 M Stocks
Jan 1, 2024
51.12 M Stocks
Jan 1, 2025
51.15 M Stocks
Jan 1, 2026 (e)
51.15 M Stocks
Jan 1, 2027 (e)
51.15 M Stocks
Jan 1, 2028 (e)
51.15 M Stocks

Laboratorios Farmaceuticos ROVI Dividend History

18 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.94EUR↓ 15.3%1×
Jul 14, 20250.94EUR↓ 15.3%1/1
20241.10EUR↓ 14.7%1×
20231.29EUR↑ 35.4%1×
20220.96EUR↑ 150.7%1×
20210.38EUR↑ 117.7%1×
20200.18EUR↑ 119.4%1×
20190.08EUR↓ 33.9%1×
20180.12EUR↓ 34.0%1×
20170.18EUR↑ 31.7%1×
20160.14EUR↓ 17.8%1×

Laboratorios Farmaceuticos ROVI dividend history and estimates

In 2025, Laboratorios Farmaceuticos ROVI paid a dividend amounting to 0.94 EUR. Dividend means that Laboratorios Farmaceuticos ROVI distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.38 EUR
0.00 EUR
Jan 1, 2022
0.96 EUR
0.00 EUR
Jan 1, 2023
1.29 EUR
0.00 EUR
Jan 1, 2024
1.10 EUR
0.00 EUR
Jan 1, 2025
0.94 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
1.12 EUR
Jan 1, 2027 (e)
0.00 EUR
1.35 EUR
Jan 1, 2028 (e)
0.00 EUR
1.62 EUR

Laboratorios Farmaceuticos ROVI dividend payout ratio

In 2025, Laboratorios Farmaceuticos ROVI had a payout ratio of 34.06%. The payout ratio indicates the percentage of the company's profits that Laboratorios Farmaceuticos ROVI distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
13.42 %
Jan 1, 2022
25.54 %
Jan 1, 2023
39.36 %
Jan 1, 2024
41.22 %
Jan 1, 2025
34.06 %
Jan 1, 2026 (e)
43.69 %
Jan 1, 2027 (e)
39.01 %
Jan 1, 2028 (e)
38.41 %

Current Laboratorios Farmaceuticos ROVI forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.91 %
Buy
81.25 % (13)
Hold
18.75 % (3)
Sell
0.00 % (0)
12M Price Target
85.07
Last Price
58.55
Currency
EUR
12M Return Potential
45.29 %
LTM Return
0 %

Laboratorios Farmaceuticos ROVI Earnings Calls

Laboratorios Farmaceuticos ROVI Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
11/5/20200.18EUR-100.52 MEUR-2020 Q3
7/27/20200.14EUR-94.17 MEUR-2020 Q2
5/13/20200.14EUR-91.47 MEUR-2020 Q1
2/26/20200.08EUR-103.12 MEUR-2019 Q4
11/7/20190.13EUR-89.00 MEUR-2019 Q3
7/30/20190.09EUR-88.13 MEUR-2019 Q2
5/8/20190.09EUR-81.35 MEUR-2019 Q1
2/26/20190.01EUR-82.37 MEUR-2018 Q4
11/6/20180.06EUR-71.88 MEUR-2018 Q3
7/26/20180.13EUR-74.45 MEUR-2018 Q2

EESG©

Eulerpool ESG Scorecard© for the Laboratorios Farmaceuticos ROVI stock

81/100
97
Environment
99
Social
47
Governance
E

Environment

20
Scope 1 - Direct Emissions9,565.8
Scope 2 - Indirect emissions from purchased energy9,243.18
Scope 3 - Indirect emissions within the value chain12,099.63
Total CO₂ emissions18,808.98
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees52.526
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Laboratorios Farmaceuticos ROVI shareholder structure

% Name
58.21927%
Norbel Invesrsiones, S.L.
Norbel Invesrsiones, S.L.
9.14544%
Indumenta Pueri, S.L.
Indumenta Pueri, S.L.
1.22583%
T. Rowe Price International Ltd
T. Rowe Price International Ltd
1.17273%
INVESCO Asset Management Limited
INVESCO Asset Management Limited
1.15898%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.04664%
ProfitlichSchmidlin AG
ProfitlichSchmidlin AG
...

Laboratorios Farmaceuticos ROVI Beneficial Ownership Filings (SEC 13D/G)

Free Float
31.7%
Float Shares
-
Shares Outstanding
-

Laboratorios Farmaceuticos ROVI Executives and Management Board

20 members · 40 % women

JE

Mr. Juan Lopez-Belmonte Encina

Executive Chairman of the Board, Chief Executive Officer · since 2007

1.86 M EUR

Management

JE

Mr. Javier Lopez-Belmonte Encina

First Executive Vice Chairman of the Board, Chief Financial Officer, General Manager of Industrial Operations · since 2001

729,000.00 EUR
IE

Mr. Ivan Jorge Lopez-Belmonte Encina

Second Executive Vice Chairman of the Board, Chief Commercial and Development Officer · since 2007

721,000.00 EUR

Board of Directors

MP

Mr. Marcos Pena Pinto

Lead External Independent Director

80,000.00 EUR
MT

Ms. Marina Del Corral Tellez

Proprietary Director

80,000.00 EUR
FG

Ms. Fatima Banez Garcia

Independent Director

80,000.00 EUR
TS

Ms. Teresa Corzo Santamaria

Independent Director

80,000.00 EUR
MC

Ms. Marta Campos

Director - Finance and Investor Relations

–
MS

Ms. Mercedes Benitez Del Castillo Sanchez

Director - Legal

–

Laboratorios Farmaceuticos ROVI Supply Chain

Laboratorios Farmaceuticos ROVI Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#Nameβ 1YTrend
1
Enervit SpA
Supplier·Customer·Personal Products·IT
0.17
-0.01
-0.01
0.13
0.07
0.80
—
2
Astellas Pharma
Supplier·Customer·Pharmaceuticals·JP
-0.02
0.53
-0.44
-0.34
-0.03
0.68
-0.03
3
Elecnor
Supplier·Construction & Engineering·ES
-0.01
-0.67
-0.75
-0.44
0.19
0.62
0.28
4
Moderna
Supplier·Customer·Biotechnology·US
0.15
0.28
0.56
0.36
-0.48
0.60
-0.92
#Nameβ 1YTrend
1
Novartis
Supplier·Customer·Pharmaceuticals·CH
0.15
0.64
-0.81
-0.68
-0.34
0
-0.68
2
Merck & Co
Supplier·Customer·Pharmaceuticals·US
0.42
-0.60
-0.77
-0.60
0
0.25
0.00

Frequently asked questions about Laboratorios Farmaceuticos ROVI

The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.

Laboratorios Farmaceuticos ROVI SA is primarily active in the pharmaceutical industry.

The main competitors of Laboratorios Farmaceuticos ROVI SA in the market include pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Sanofi.

Laboratorios Farmaceuticos ROVI SA is a renowned pharmaceutical company with an impressive history and background. Established in 1946, ROVI SA has consistently focused on developing and manufacturing innovative healthcare solutions. With its headquarters in Madrid, Spain, the company operates in various therapeutic areas, including Special Focused Medicines, Biosimilars, and Active Pharmaceutical Ingredients (APIs). ROVI SA has a strong commitment to research and development, striving to improve patients' quality of life through cutting-edge treatments. Over the years, the company has gained recognition and trust from healthcare practitioners and patients alike, solidifying its position as a prominent player in the pharmaceutical industry.

Laboratorios Farmaceuticos ROVI SA has achieved several significant milestones throughout its history. One noteworthy achievement is its development of innovative pharmaceutical products, including advanced drug delivery systems and therapeutic solutions. The company has also gained recognition for its expertise in biopharmaceutical manufacturing and has successfully established numerous strategic partnerships globally. Additionally, Laboratorios Farmaceuticos ROVI SA has demonstrated consistent growth and profitability, expanding its market presence and enhancing shareholder value. These achievements reflect the company's commitment to delivering high-quality healthcare solutions and driving advancements within the pharmaceutical industry.

Laboratorios Farmaceuticos ROVI SA is primarily present in Spain, where the company is based. Additionally, ROVI has a global presence, with its products and services being available in several other countries and regions around the world. These include various European countries such as Germany, France, Italy, Portugal, and the United Kingdom. Furthermore, ROVI has a significant presence in the Americas, including Mexico, Brazil, and Colombia. With its international reach, Laboratorios Farmaceuticos ROVI SA has established a strong presence in both European and American markets, catering to a wide range of customers and expanding its global footprint.

Laboratorios Farmaceuticos ROVI SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered on the development and manufacturing of innovative medicines and healthcare products, ROVI prioritizes patient well-being and strives for scientific advancement. The company's commitment to research and development, along with its focus on partnerships with healthcare professionals and organizations, enables ROVI to provide innovative solutions that improve patients' lives. By embracing a culture of responsibility, transparency, and ethical practices, Laboratorios Farmaceuticos ROVI SA aims to contribute to global healthcare and deliver value to its stakeholders.

Analysts currently set an average price target of 84.26 EUR for the Laboratorios Farmaceuticos ROVI stock (median: 85.07 EUR), implying +43.9 % versus the latest price. The consensus is based on 16 analyst ratings.

Laboratorios Farmaceuticos ROVI Analyst Price Targets 2026

16 analysts currently rate the Laboratorios Farmaceuticos ROVI stock: 13 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Laboratorios Farmaceuticos ROVI to generate revenue of 771.18 M EUR and earnings per share of 2.57 EUR.

Laboratorios Farmaceuticos ROVI Analyst Price Targets 2026

The Laboratorios Farmaceuticos ROVI share (ROVI.MC) is listed on 9 stock exchanges, including: Frankfurt (41L.F), München (41L.MU), Düsseldorf (41L.DU), London (0ILL.L), London (0ILL.L), SIX (Zürich) (41L.SW).

Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the development and production of biotechnological drugs, vaccines, and generics. The company was founded in Spain in 1946 and has since built an impressive track record. Today, ROVI is a global player with customers in over 80 countries worldwide. ROVI operates in three business segments: Innovation, Generics, and Specialties. In the Innovation segment, the company focuses on biotechnological drugs and vaccines, with a particular emphasis on tissue repair, kidney and liver diseases, and immuno-oncology. The pipeline of Innovation includes a variety of innovative drugs in various stages of clinical development. A significant milestone for the company was the successful approval of Doria®, an inactivated SARS-CoV-2 vaccine for individuals aged 18 years and older. In the Generics segment, ROVI focuses on high-quality generics for various diseases. The company has strong partnerships worldwide, giving it access to a broad network of producers and suppliers. ROVI is an important supplier to the public health sector in many countries. The Specialties segment comprises different products, such as contrast agents for medical imaging, wound care, and non-surgical wrinkle treatment. ROVI's product range includes a variety of drugs and vaccines for different diseases and applications. Some of the most well-known products are Envarsus® for preventing transplant rejection in kidney or liver transplantations, Bemiparin as an anticoagulant for the prevention and treatment of thrombosis, and Hepacare® for the treatment of Hepatitis C, used in countries like Pakistan to reduce the spread of the disease. To meet the growing needs of the healthcare market, ROVI has invested in research and development. The company has expanded its research and development pipeline and works on developing innovative drugs and products. ROVI is also known for investing in partnerships. The company collaborates closely with other bio-pharmaceutical companies and research institutes to develop new drugs. These partnerships also open up new markets and provide access to new technologies. In summary, ROVI SA has been active as a strategic and influential company in the biopharmaceutical world. Investments in research and development, innovation, and partnerships have contributed to ROVI's recognition in the industry. With a wide network of producers and suppliers worldwide and customers in over 80 countries, ROVI is globally present and has established a strong position in the public health sector.

The expected revenue of Laboratorios Farmaceuticos ROVI is 771.18 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Laboratorios Farmaceuticos ROVI is 131.54 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Laboratorios Farmaceuticos ROVI is currently 22.87. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Laboratorios Farmaceuticos ROVI stock.

The price-to-sales ratio (P/S) of Laboratorios Farmaceuticos ROVI is currently 3.90. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Laboratorios Farmaceuticos ROVI stock.

The Eulerpool Quality Score for Laboratorios Farmaceuticos ROVI is 6/10.

The ISIN of Laboratorios Farmaceuticos ROVI is ES0157261019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Laboratorios Farmaceuticos ROVI is A0M0GQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Laboratorios Farmaceuticos ROVI is ROVI.MC. The ticker symbol is used to trade Laboratorios Farmaceuticos ROVI shares on the stock exchange.

Over the past 12 months, Laboratorios Farmaceuticos ROVI paid a dividend of 0.94 EUR . This corresponds to a dividend yield of about 1.59 %. For the coming 12 months, Laboratorios Farmaceuticos ROVI is expected to pay a dividend of 1.35 EUR.

The current dividend yield of Laboratorios Farmaceuticos ROVI is 1.59 %.

Laboratorios Farmaceuticos ROVI pays a dividend, distributed in the months of , , , .

Laboratorios Farmaceuticos ROVI paid dividends every year for the past 18 years.

For the upcoming 12 months, dividends amounting to 1.35 EUR are expected. This corresponds to a dividend yield of 2.30 %.

Laboratorios Farmaceuticos ROVI is assigned to the 'Health' sector.

To receive the latest dividend of Laboratorios Farmaceuticos ROVI from amounting to 0.94 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Laboratorios Farmaceuticos ROVI distributed 1.1 EUR as dividends.

The dividends of Laboratorios Farmaceuticos ROVI are distributed in EUR.

All fundamentals and in-depth analysis of Laboratorios Farmaceuticos ROVI

Our stock analysis for Laboratorios Farmaceuticos ROVI stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Revenue→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Net Income→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI P/E→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI P/S→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI EBIT→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Dividend→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Directors Dealings→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Stocks→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Market capitalization→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Debt→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Liabilities→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Equity→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI AAQS→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Employees→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI ROE→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI ROA→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI ROCE→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI News→
Laboratorios Farmaceuticos ROVI Stock
Laboratorios Farmaceuticos ROVI Analyst Price Targets→

Health Stocks

Laboratorios Richmond SACIFLaboratorio Reig JofreLaboratory Corporation of America HoldingsLaboratoires EuromedisLabTurbo BiotechLabocannaLactose (India)Labiana HealthLadprao General Hospital PCLLabgenomics CoLaeknaL&K Biomed CoAll Stocks A–Z →